Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02138539 · ClinicalTrials.gov registry record · Phase 4
Evaluation of an Herbal-Based De-Pigmenting System
A Phase 4 study of Melasma and Hyperpigmentation, sponsored by Sadick Research Group.
- Completed
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT02138539: Completed Phase 4 study of Melasma and Hyperpigmentation, sponsored by Sadick Research Group.
NCT02138539 is a Phase 4 study of Melasma and Hyperpigmentation that has completed, run by Sadick Research Group. The registered enrollment target is 28 participants, below the 42-participant average among 8 other Melasma trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02138539, a Phase 4 study of Melasma and Hyperpigmentation, has completed, sponsored by Sadick Research Group.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effectiveness and tolerability of an herbal de-pigmenting regimen applied to one side of the face compared with hydroquinone applied to the other side of the face in treating mottled hyperpigmentation and melasma.
Primary Outcome
The melanin index of the skin will be measured at baseline and at each follow-up visit with a non-invasive device. At the end of the study, the change of the Melanin index over a period of 6 months will be calculated.
Conditions Studied
Interventions
- OTHER Herbal depigmenting agent (Epionce)
- DRUG Hydroquinone
Study Locations (1)
New York
- Sadick Research Group - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-10 |
| Phase | Phase 4 |
What the finished NCT02138539 record still lists
NCT02138539 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 42-participant average among 8 other Melasma trials with a reported enrollment target (33% lower).
The record links to 2 conditions, with Melasma appearing as the primary indexed condition, and to 2 interventions - of which Herbal depigmenting agent (Epionce) is the first listed.
NCT02138539 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02138539 about?
NCT02138539 is a clinical study titled "Evaluation of an Herbal-Based De-Pigmenting System". The purpose of this study is to evaluate the effectiveness and tolerability of an herbal de-pigmenting regimen applied to one side of the face compared with hydroquinone applied to the other side of the face in treating mottled hyperpigmentation and melasma.
What is the current status of trial NCT02138539?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2013-10. Estimated completion is 2014-10.
What conditions does trial NCT02138539 study?
This clinical trial studies the following conditions: Melasma, Hyperpigmentation.
What interventions are being tested in trial NCT02138539?
The interventions under investigation include: Herbal depigmenting agent (Epionce) (OTHER), Hydroquinone (DRUG).
Who is sponsoring clinical trial NCT02138539?
This trial is sponsored by Sadick Research Group, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02138539 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melasma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02138539's enrollment target sits among peer trials
28 3rd of 8 higher than 6 of 8 other Melasma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melasma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women
COMPLETED · Phase 4
-
Sylfirm X Radiofrequency Microneedling for the Treatment of Melasma
RECRUITING · NA
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
-
LaseMD System for the Treatment of Melasma
ACTIVE NOT RECRUITING · NA
-
Efficacy and Safety of PiQo4 Device for Treatment of Melasma
COMPLETED · NA
-
Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia